A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00163098
First received: September 8, 2005
Last updated: October 12, 2006
Last verified: October 2006

September 8, 2005
October 12, 2006
December 2004
Not Provided
Effect on exercise tolerance
Same as current
Complete list of historical versions of study NCT00163098 on ClinicalTrials.gov Archive Site
Effect on lung function and quality of life
Same as current
Not Provided
Not Provided
 
A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Pulmonary Disease, Chronic Obstructive
Drug: UK-369,003
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
136
December 2005
Not Provided

Inclusion Criteria:

  • GOLD criteria 2 to 4
  • 10 pack year history of smoking

Exclusion Criteria:

  • Women of child bearing potential
Both
35 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Germany,   India,   United Kingdom
 
NCT00163098
A3711028
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP